RFK Jr. Proposes FDA Look the Other Way on Unproven Peptides

A report says Health Secretary Robert F. Kennedy Jr. has proposed that the Food and Drug Administration take a hands-off approach to peptides, a class of compounds that has grown popular with consumers and online sellers. Under the proposal, the agency would effectively look the other way rather than enforce its rules against them.

The most striking detail comes from inside the agency. According to the report, FDA scientists have said that none of the popular peptide drugs have been proven safe or effective. That puts the agency's own staff at odds with the department's leadership on a question that directly affects what people can buy and inject.

Peptides are short chains of amino acids. Some are approved as prescription medicines, but many of the products drawing attention are sold outside that approval process, often marketed for things like recovery, fitness or anti-aging. The gap between approved drugs and widely sold products is where enforcement matters most. If regulators stop pursuing a category of products, sellers face less risk, while buyers get less assurance about what is actually in the vial.

The summary leaves open how the proposal would work in practice, what formal steps would follow, and whether it would hold up to legal or congressional scrutiny. Those are the questions to watch. Drugmakers, compounding pharmacies and consumer safety advocates will likely track any move to deprioritize enforcement closely.

For now, the central fact is the one the FDA's own scientists have put on the record: none of the popular drugs have been shown to be safe or effective.